cyclin δ-1 Inhibitors

Chemical inhibitors of cyclin δ-1 can exert their inhibitory action through various mechanisms that ultimately impede the protein's activity, which is closely related to cell cycle progression. Palbociclib, Ribociclib, and Abemaciclib are known to inhibit cyclin-dependent kinase 4/6 (CDK 4/6), critical enzymes that, when activated, lead to the phosphorylation of the retinoblastoma (Rb) protein. This phosphorylation event is a prerequisite for cell cycle progression from the G1 phase to the S phase, and as such, inhibition of CDK 4/6 activity results in Rb remaining in an unphosphorylated state, which prevents the cell cycle from advancing. Consequently, cyclin δ-1, whose activity is contingent upon cell cycle progression, is indirectly inhibited due to the cell being arrested in the G1 phase.

Flavopiridol and Roscovitine target a broader spectrum of cyclin-dependent kinases, not only including CDK 4/6 but also other CDKs pivotal for cell cycle regulation. By impeding these kinases, these inhibitors contribute to a halt in cell cycle progression, leading to the downregulation of cyclin δ-1 activity as the cell cycle is a primary determinant of its function. Similarly, Dinaciclib and Milciclib operate by inhibiting multiple CDKs, which not only results in cell cycle arrest but also diminishes the activity of cell cycle-related proteins, including cyclin δ-1. SNS-032 and CDK9 Inhibitor II primarily affect CDK9, which plays a crucial role in transcription elongation. By inhibiting CDK9, the transcription of genes essential for cell cycle progression is disrupted, thereby indirectly inhibiting cyclin δ-1. Alsterpaullone, AT7519, and PHA-793887, by targeting several CDKs, also induce cell cycle arrest, thereby reducing the functional activity of cyclin δ-1, which is dependent on the cell cycle's dynamic state.